Lilly will invest more than $700M to boost global insulin production

11/14/2013 | Genetic Engineering & Biotechnology News

Eli Lilly and Co. said it plans to expand its global insulin production capacity in Indiana, Puerto Rico, China and France in response to growing demand for the diabetes treatment. The firm, which has 14 candidates for the treatment of diabetes and related complications in its pipeline, will invest more than $700 million in the expansion project.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA